Sugi Predict

Sugi Predict / Compounds / SCHEMBL4129868

SCHEMBL4129868

SCHEMBL4129868

CCOC(=O)Nc1ccc(C(=O)Cl)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.58
▸ NPC1 O15118 5/20 0.58
▸ HPGD P15428 3/20 0.58
▸ CRHBP P24387 1/20 0.58
▸ CRHR2 Q13324 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ ALDH1A1 P00352 3/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ KDM4E B2RXH2 2/20 0.53
▸ TSHR P16473 3/20 0.52
▸ LMNA P02545 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.52
▸ NAMPT P43490 1/20 0.52
▸ CASP1 P29466 1/20 0.51
▸ CYP1A2 P05177 2/20 0.50
▸ CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7565510 0.87 RAB9A (0.71) RAB9ANPC1HPGDCRHBPCRHR2
SCHEMBL10668920 0.84 RAB9A (0.64) RAB9ANPC1HPGDCRHBPCRHR2
SCHEMBL6002968 0.84 RAB9A (0.59) RAB9ANPC1HPGDCRHBPCRHR2
SCHEMBL10941324 0.84 NAMPT (0.69) RAB9ANPC1HPGDMAPTSMN1; SMN2
SCHEMBL15127704 0.83 RAB9A (0.58) RAB9ANPC1HPGDCRHBPCRHR2
SCHEMBL25845708 0.83 SMN1; SMN2 (0.77) RAB9ANPC1HPGDCRHBPCRHR2
SCHEMBL5636399 0.83 RAB9A (0.72) RAB9ANPC1HPGDCRHBPCRHR2
SCHEMBL1187952 0.82 L3MBTL1 (0.77) RAB9ANPC1HPGDCRHBPCRHR2
SCHEMBL11047592 0.82 L3MBTL1 (0.68) RAB9ANPC1HPGDCRHBPCRHR2
SCHEMBL7565512 0.82 RAB9A (0.70) RAB9ANPC1HPGDCRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181966-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-07-16 — — US disclosed
US-7504508-B2 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-03-17 — — US disclosed
US-7211672-B2 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-05-01 — — US disclosed
EP-1740547-A1 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-01-10 — — EP disclosed
EP-1087946-B1 ARYL ALKANOYLPYRIDAZINES MERCK PATENT GMBH (DE) 2007-01-10 — — EP disclosed
US-20060106061-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. 2006-05-18 — — US disclosed
CN-1720047-A PgD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARM INC (US) 2006-01-11 — — CN disclosed
US-20050256158-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. 2005-11-17 — — US disclosed
WO-2005100321-A1 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-10-27 — — WO disclosed
EP-1556047-A2 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-07-27 — — EP disclosed
CN-1168720-C Aryl alkanoylpyridazines Ĭ��ר���ɷ����޹�˾ 2004-09-29 — — CN disclosed
US-20040082609-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 — — US disclosed
WO-2004032848-A2 PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES MILLENNIUM PHARMACEUTICALS, INC. (US) 2004-04-22 — — WO disclosed
US-6417188-B1 ENZYME INHIBITORS OF PHOSPHODIESTERASE MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2002-07-09 — — US disclosed
CN-1305465-A Aryl alkanoylpyridazines MERCK PATENT GMBH (DE) 2001-07-25 — — CN disclosed
EP-1087946-A1 ARYL ALKANOYLPYRIDAZINES MERCK PATENT GmbH (DE) 2001-04-04 — — EP disclosed
WO-1999065880-A1 ARYL ALKANOYLPYRIDAZINES MERCK PATENT GMBH (DE) 1999-12-23 — — WO disclosed
EP-0433451-A1 OXIME DERIVATIVES AND HERBICIDES CONTAINING THE SAME AS AN ACTIVE INGREDIENT TEIJIN LIMITED (JP) 1991-06-26 — — EP disclosed
WO-1990001874-A1 OXIME DERIVATIVES AND HERBICIDES CONTAINING THE SAME AS AN ACTIVE INGREDIENT TEIJIN LIMITED (JP) 1990-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256158-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases PTGDR2, LTB4R2, CYSLTR2 RAB9A 2883/4885NPC1 2683/4885HPGD 120/4885
US-20060106061-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases PTGDR2, LTB4R2, CYSLTR2 RAB9A 2765/4885NPC1 2856/4885HPGD 112/4885
US-20090181966-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases PTGDR2, LTB4R2, CYSLTR2 RAB9A 2883/4885NPC1 2683/4885HPGD 120/4885
US-20040082609-A1 PGD2 receptor antagonists for the treatment of inflammatory diseases PTGDR2, PTGDR, LTB4R2 RAB9A 3346/4885NPC1 3162/4885HPGD 59/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.